Hematopoiesis, Hematologic Malignancies & Immunology
The central themes of the Hematopoiesis, Hematologic Malignancies, and Immunology (HMI) Program are: (1) Hematopoiesis; (2) Hematologic Malignancies; (3) Immunology. The ultimate programmatic goal of the program is to use results from member studies to develop novel therapeutic approaches for treating patients with malignancies. These comprehensive studies include basic normal and disordered hematopoiesis, the pathophysiology of hematologic malignancies and immune cell function associated with hematopoiesis, hematopoietic cell transplantation and tumors.
Scientific goals: The scientific goals of the program are advanced by focused work in three themes:
Theme 1: Hematopoiesis
Aim 1: Enhance engraftment of hematopoietic stem cells for clinical cord blood, bone marrow, and mobilized peripheral blood transplantation.
Aim 2: Enhance mobilization of hematopoietic stem cells/hematopoietic progenitor stem cells for collection for clinical use.
Aim 3: Characterize cell and molecular biology of self-renewal, proliferation, survival, differentiation and migration of hematopoietic stem cells/hematopoietic progenitor stem cells in the context of cytokine and microenvironmental interactions.
Theme 2: Hematologic Malignancies
Aim 1: Determine changes in cancer and bone cell interactions that enhance tumor growth, bone destruction and angiogenesis to identify therapeutic targets for treatment of hematologic malignancies.
Aim 2: Identify genes linked by intracellular signaling pathways that decrease tumor suppressor expression and exploit as targets for treating hematologic malignancies.
Aim 3: Determine efficacy of novel approaches for treatment of hematologic malignancies.
Theme 3: Immunology
Aim 1: Enhance anti-tumor immunity to treat hematologic malignancies.
Aim 2: Characterize immune cells and modulate graft-vs.-host disease and graft versus leukemia after hematopoietic cell transplantation.